Bioagilytix Secures Significant New Investment From Global Investor Cinven To Fuel Continued Long-Term Growth
Nov 17, 2021•about 4 years ago
Description
BioAgilytix, a leading global contract research organization (CRO), today announced an agreement to be further capitalized by Cinven, a leading international private investment firm focused on building world-class global companies. Cinven will acquire a majority stake in BioAgilytix while current majority investor Cobepa, S.A., a Brussels-based private investment firm, will remain a significant minority investor in the Company.